Abstract 305P
Background
Actionable mutation detection by targeted multiple gene panel sequencing is increasingly becoming a routine test in the clinical treatment of non-small cell lung cancer. Although it helps patients choose their own personalized drugs, most mainly focused on single actionable event and ignored the other driver variation which could affect the efficacy of the targetable drugs and patients’ outcome.
Methods
Fresh frozen tumors, pleural effusion or FFPE tumors with matched peripheral blood were collected from 235 patients with lung adenocarcinoma (LUAD) before therapy. All of the samples were sequenced using commercial gene panel OseqTM series. The genetic molecular profiles, correlations between genetic variations and patient's prognosis were analyzed.
Results
A total of 1713 somatic variations were detected in our cohort including single-nucleotide variants, insertion/deletions, copy number alterations and structural variations. Over 50% of patients carried either EGFR or TP53 alteration. The tumor variant allele frequency of TP53 was a prognostic indicator for LUAD patient. The co-occurring genomic alterations were associated with patients' outcome, especially for genes co-mutated with EGFR, ERBB2 and KDR in the EGFR tyrosine kinase inhibitor resistance pathway. In addition, MYC amplification alone was insufficient as an independent prognostic predictor for LUAD. Moreover, the DNA damage repair genes including ATM, BRCA1and BRCA2 were more likely to alter in patients with wild-type TP53 (TP53wt). The alterations on STK11 and KRAS were enriched in TP53wt and DDRmut individuals and slightly corelated with prognosis of LUAD patients.
Conclusions
We presented an integrated analysis of genetic and clinical outcome features in LUAD cohort. Several novel pairs of concurrent gene variation were found which associated with patients' survival and could be prognostic predictors for treatment evaluation. Our work also shed further light on the genomic subtyping based on DDR genes as promising prognostic biomarkers in LUAD and provide a larger picture of multiple gene sequencing for helping to find optimal treatment in precision anticancer therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session